ASP Isotopes

ASP Isotopes Operating Expenses

The Total Operating Expenses of ASP Isotopes (ASPI) as of Nov 18, 2026 is 60.60 M USD. In the previous year, Total Operating Expenses was 27.95 M USD — a change of 116.78% (higher).

Operating Expenses

60.60 MUSD

YoY

116.78%

Last updated:

Total Operating Expenses of ASP Isotopes is 2025 60.60 M USD. Total Operating Expenses of ASP Isotopes was 2024 27.95 M USD. It decreases by 116.78% higher compared to the previous year.

The ASP Isotopes Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2019
7.03 M USD
Jan 1, 2021
41,610.00 USD
Jan 1, 2022
5.10 M USD
Jan 1, 2023
16.18 M USD
Jan 1, 2024
27.95 M USD
Jan 1, 2025
60.60 M USD
The ASP Isotopes Operating Expenses history
YEAROperating ExpensesYoY
60.60 MUSD+116.78%
27.95 MUSD+72.75%
16.18 MUSD+217.33%
5.10 MUSD+12,154.38%
41,610.00USD-99.41%
7.03 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ASP Isotopes Stock analysis

What does ASP Isotopes do? ASP Isotopes, Inc. generates revenue through the development and commercialization of enriched isotopes using its Aerodynamic Separation Process (ASP technology). The company focuses on producing Carbon-14 (C-14), Molybdenum-100 (Mo-100), and Silicon-28 (Si-28) for specialized markets, with plans to expand into Uranium-235 (U-235) for the nuclear energy sector. Its subsidiaries, ASP Isotopes Guernsey Limited and Enriched Energy LLC, handle high-value isotope production and uranium development, respectively. The company licenses ASP technology from Klydon Proprietary Ltd for all isotope-related activities. The target customers for C-14, Mo-100, and Si-28 are highly specialized end markets requiring low-volume, high-value isotopes. Enriched Energy LLC specifically targets the nuclear energy market with uranium products. ASP Isotopes Guernsey Limited focuses on niche applications where isotope enrichment is critical, such as medical and industrial uses. The company’s revenue model relies on the sale of these enriched isotope products to specialized industries rather than mass-market consumers. ASP Isotopes, Inc. operates under a pre-commercial stage, meaning it is still developing its production capabilities and has not yet achieved full-scale commercialization. The company’s initial revenue streams will come from the sale of C-14, Mo-100, and Si-28, with future expansion into U-235 expected to diversify its product portfolio. The Aerodynamic Separation Process (ASP technology) is central to its business model, enabling the enrichment of natural isotopes into higher concentration products for specialized applications. ASP Isotopes is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ASP Isotopes stock

Total Operating Expenses of ASP Isotopes is 60.60 M USD in 2025.

Total Operating Expenses of ASP Isotopes changed from 27.95 M USD to 60.60 M USD, representing a 116.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses ASP Isotopes since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's ASP Isotopes historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ASP Isotopes

All Key Metrics — ASP Isotopes